返回Google圖書搜尋

A Clinical and Economic Review of HMG-CoA Reductase Inhibitors in Coronary Heart Disease

其他書名	Based Primarily on the Technical Report--HMG-CoA Reductase Inhibitors : a Review of Published Clinical Trials and Pharmacoeconomic Evaluations
出版	Canadian Coordinating Office for Health Technology Assessment, 1998
URL	http://books.google.com.hk/books?id=naadswEACAAJ&hl=&source=gbs_api

註釋Abnormalities in blood lipid levels, such as decreased high density lipoprotein (HDL) and elevated total cholesterol (TC), triglycerides, low density lipoproteins, very low density lipoproteins and TC/HDL ratios, have been linked to an increase in the risk of developing coronary heart disease (CHD). Pharmacological interventions aimed at lowering lipid levels have been demonstrated to decrease CHD and, more recently, to decrease coronary events and overall mortality. Whether a given patient should be started on lipid lowering therapy, the duration of treatment, and which agent to use has been difficult to answer due to the limited duration of clinical trials, and the absence of data on long-term safety, effectiveness and cost-effectiveness. This review attempts to address these issues, particularly as they relate to statin therapy. The primary objectives are: to review the efficacy of HMG-CoA reductase inhibitors (i.e. statins); to review whether there is evidence to suggest differences exist among the statins; to determine which population(s) would most likely benefit from statins; to review the costs and cost-effectiveness of statins.